Dr. Prasanth Ravipati, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 242
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MN license 67537 -
Internal Medicine Physician
NE license 7232 · NE license 30286
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bellevue Medical Center Bellevue, NE
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 242
- Services billed
- 489
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 184 | 88 |
| Hemodialysis procedure with physician evaluation | 162 | 75 |
| Established patient office or other outpatient visit, 20-29 minutes | 73 | 56 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 58 | 12 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 55 | 53 |
| Dialysis procedure including 1 evaluation | 41 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Torsemide Other prescribers in Omaha, NE | 50 |
| Losartan Potassium Other prescribers in Omaha, NE | 46 |
| Amlodipine Besylate Other prescribers in Omaha, NE | 31 |
| Chlorthalidone Other prescribers in Omaha, NE | 24 |
| Tamsulosin Hcl Other prescribers in Omaha, NE | 23 |
| Hydrochlorothiazide Other prescribers in Omaha, NE | 21 |
| Jardiance (empagliflozin) Other prescribers in Omaha, NE | 20 |
| Spironolactone Other prescribers in Omaha, NE | 19 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Omaha, NE | 16 |
| Nifedipine Er (nifedipine) Other prescribers in Omaha, NE | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $140 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $124 |
|---|---|
| Fresenius USA Marketing, Inc. | $15.91 |
| Food and Beverage | $140 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $50,354 in research payments for these studies, mostly to the institutions running them.
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646 - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.